New paclitaxel-cisplatin based chemotherapy regimen for advanced stage, recurrent, or refractory neuroblastoma - Preliminary report

Medical and Pediatric Oncology

Volumn 40, Issue 2, 2003, Pages 130-132

  Surico, Giammarco ^a,b   Muggeo, Paola ^a   De Leonardis, Francesco ^a   Rigillo, Nicola ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

Cisplatin; Neuroblastoma; Paclitaxel; Pediatric oncology

Indexed keywords

CISPLATIN; PACLITAXEL;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONFERENCE PAPER; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; FEMALE; HUMAN; INFANT; INFUSION; MALE; NAUSEA; NEUROBLASTOMA; PAPULAR SKIN DISEASE; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; VOMITING;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; FATAL OUTCOME; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; PACLITAXEL; RETROPERITONEAL NEOPLASMS; SALVAGE THERAPY; TAXOIDS;

EID: 0037291530     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10106     Document Type: Conference Paper

References (10)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: JB Lippincott Company; 1993, p 739-767.
2. McGuire WP, Rowinsky EK, editors. Paclitaxel in Cancer Treatment. New York: Marcel Dekker, Inc.; 1995, p 201-305.
3. Riccardi A, Servidei T, Tornesello A, et al, Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer 1995;31A:494-499.
4. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991;9:1692-1703.
5. Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent of advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 1999;17:2676-2680.
6. Hurwitz CA, Relling MV, Weitman SD, et al. Phase I trial of paclitaxel in children with refractory solid tumors: A Pediatric Oncology Group Study, J Clin Oncol 1993;11:2324-2329.
7. Fennelly D, Aghajanian C, Shapiro F, et al, Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-192.
8. Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994;12:532-538.
9. Helson L, Helson C, Malik S, et al. A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells. Anticancer Drugs 1993;4:487-490.
10. Fizazi K, Zelek L. Is one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 2000;11:133-149.